Skip to content

Efficacy and safety of neostigmine in severe acute pancreatitis patients: a randomized controlled trial

Efficacy and safety of neostigmine in severe acute pancreatitis patients: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058305
Enrollment
Unknown
Registered
2022-04-05
Start date
2022-05-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Interventions

Intervention group:neostigmine
Control group:normal saline

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 years (inclusive) and 75 years (inclusive); 2. Diagnosed with acute lipogenic pancreatitis or acute alcoholic pancreatitis; 3. See a doctor within 24 hours of the onset of illness; 4. Evidence of organ failure.

Exclusion criteria

Exclusion criteria: 1. Neostigmine allergy; 2. There is a taboo of ShinZ muscle injection: (1) Epilepsy; (2) Angina pectoris, arrhythmia, ventricular tachycardia, sinus bradycardia; (3) Mechanical intestinal obstruction, urinary obstruction, asthma; (4) Uncontrolled hypotension and elevated vagal tone; 3. Pregnancy; 4. Uncontrolled hypertension or other cardiovascular and cerebrovascular diseases.

Design outcomes

Primary

MeasureTime frame
voluntary defecation recovery time;

Secondary

MeasureTime frame
borborygmus;intra-abdominal pressure;intra-abdominal infection;hospital stay;

Countries

China

Contacts

Public ContactZhu Huadong

Peking Union Medical College Hospital

sh610030409@163.com+86 17600112173

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026